To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: FDA Approves Velosulin BR For Diabetes Treatment URL: http://www.pslgroup.com/dg/115ADA.htm Doctor's Guide July 20, 1999
PRINCETON, NJ -- July 20, 1999 -- The United States Food and Drug Administration has approved Novo Nordisk A/S' Velosulin(R)BR (human buffered regular insulin [rDNA origin] injection) for people with diabetes. It is indicated for use in external insulin infusion pumps and with U-100 insulin syringes. Novo Nordisk will begin marketing recombinant Velosulin BR later this year and it will eventually replace the semi-synthetic version of Velosulin BR that is currently available. The active drug in the recombinant form of Velosulin BR is structurally identical to the insulin produced by the pancreas in the human body. The formulation is not significantly different from semi- synthetic Velosulin BR, which has been available for pump use in the U.S. since 1986. In the U.S., approximately five percent of people with type I diabetes use an insulin pump to help manage their diabetes. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.